GWPRF - GW Pharma: Analysts Aren't Thinking Clearly

GW Pharmaceuticals (GWPH) reported Q1'20 earnings earlier in May, but analysts remain conservative despite strong numbers. While the name is up from the lows in March, it is still well below the 52-week high of $187.69 and I believe there is room to run.

Analyst estimates are still too conservative

When I last wrote about GWPH, I noted that I found analyst estimates for revenues to be too conservative (Table 1). At that time, 15 analysts had an average revenue estimate of $533.4M (range: $494.56M-$588.39M) for 2020.

Table 1: Revenue estimates for GWPH prior to

Read more ...